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Conversion of cellular prion protein (PrPC) into
the pathological conformer (PrPSc) has been
studied extensively by using recombinantly
expressed PrP (rPrP). However, due to inherent
difficulties of expressing and purifying post-
translationally modified rPrP variants, only a
limited amount of data is available for mem-
brane-associated PrP and its behavior in vitro
and in vivo. Here, we present an alternative
route to access lipidated mouse rPrP (rPrPPalm)
via two semisynthetic strategies. These rPrP
variants studied by a variety of in vitro methods
exhibited a high affinity for liposomes and
a lower tendency for aggregation than rPrP.
In vivo studies demonstrated that double-
lipidated rPrP is efficiently taken up into the
membranes of mouse neuronal and human
epithelial kidney cells. These latter results
enable experiments on the cellular level to
elucidate the mechanism and site of PrP-PrPSc
conversion.
INTRODUCTION
Transmissible spongiform encephalopathies (TSEs) are
infectious neurodegenerative disorders that are charac-
terized by conversion of cellular prion protein (PrPC) into
its pathological isoform, PrPSc [1–5]. These diseases
affect humans and other mammalian species such as cat-
tle (bovine spongiform encephalopathy), sheep, and goat
(scrapie). Both isoforms of PrP exhibit significant differ-
ences in their biophysical properties, although their pri-
mary structure is identical [6–9]. Common features are a
disulfide bond between a helices 2 and 3 [10] as well as
the occurrence of a mixture of non-, mono-, and diglyco-
sylated PrP variants and a C-terminal glycosylphosphati-
dylinositol (GPI) anchor [11, 12].
This latter feature is highly important for targeting PrP to
membranes, and the GPI anchor seems to be important in994 Chemistry & Biology 14, 994–1006, September 2007 ª2007the generation of PrPSc [13–15]; PrP linked to the plasma
membrane via a heterologous CD4 transmembrane do-
main (PrP-CD4) is complex glycosylated as well [16–18].
However, in a scrapie-infected mouse neuroblastoma cell
line, PrP-CD4 could not be converted into PrPSc [16, 17].
Several studies have provided substantial evidence that
the key step in prion pathogenesis, the conversion of
PrPC into PrPSc, occurs on the outer leaflet of the cell
membrane, with PrP anchored to the membrane via a C-
terminal GPI anchor [19]. Additionally, in vitro experiments
with raft preparations from PrP-infected and noninfected
cells point to the fact that colocalization of PrPC and PrPSc
is a prerequisite for conversion of PrPC into PrPSc [20–23].
Even though this seems to be direct evidence for the in-
fluence of membrane attachment of PrP on the process of
conversion, many previous studies have only been per-
formed with recombinantly produced, soluble PrP lacking
any membrane anchor [24–27]. To the best of our knowl-
edge, only three studies exist in which recombinantly ex-
pressed PrP harboring GPI anchor mimics was used to
study membrane-anchored PrPC and its transition into
PrPSc without the need for isolation of PrP from deter-
gent-resistant membranes [22, 23, 28]. In two of these
studies, GPI mimics have been introduced at the C termi-
nus of PrP via disulfide formation with specifically modi-
fied phospho- or sulfo-lipids, respectively, whereas the
third study relies on a myristoyl moiety attached via a thio-
ether bond. Here, we present two strategies for the semi-
synthesis of C-terminally modified PrP with chemically
synthesized membrane anchor peptides based on the
expressed protein ligation (EPL) approach [29] (Figure 1).
One strategy relies on the expression of rPrP in fusion
with the GyrA mini-intein and two affinity tags (His tag
and chitin-binding domain), which allow for straightfor-
ward purification of the fusion construct from cell lysates.
In order to generate rPrP with a C-terminal thioester moi-
ety for native chemical ligation reactions with synthetic
GPI anchor mimics, cleavage of the fusion protein was
induced with an excess of alkyl thiols [30]. Subsequent
addition of synthetic GPI anchor-mimicking peptides
with N-terminal cysteine residues leads to chemoselective
ligation of both reactants (Figure 1A). The second strategy
avoids the generation and separation of a rPrP thioesterElsevier Ltd All rights reserved
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Semisynthesis of Lipidated Prion ProteinFigure 1. Strategies for the Semisynthesis of rPrPPalm
(A) Generation of rPrP MESNA thioester from a rPrP-GyrA intein fusion construct expressed in E. coli.
(B) Trans-splicing reaction of a fusion construct of rPrP and the N-terminal part of the DnaE split intein (DnaEN) expressed in E. coli with chemically
synthesized GPI anchor mimic and the C-terminal part of the DnaE split intein (DnaEC). Both strategies lead to the desired rPrP carrying a C-terminal
GPI anchor mimic (rPrPPalm).species and is based on protein trans-splicing by express-
ing rPrP in fusion with the N-terminal segment of the DnaE
split intein (DnaEN) and synthesis of its C-terminal seg-
ment (DnaEC) linked to GPI anchor-mimicking peptides
[31, 32]. Both DnaE segments spontaneously associate
when correctly folded and form a functional intein, which
undergoes a series of trans-esterification steps in order
to give the desired modified rPrP (Figure 1B). The advan-
tage of our approach lies in the variety of the peptides,
which can be tailor-made and can include not only alkyl
chains in order to achieve membrane insertion, but also
fluorescent labels for localization studies in vitro and in
vivo as well as the introduction of cleavage sites for highly
selective proteases. The latter feature provides a tool for
controlled release of rPrP anchored in membranes. In
vivo experiments reveal an insertion of the lipidated rPrP
into the plasma membrane of mouse neuronal and human
epithelial kidney cells.
RESULTS
Synthesis of GPI Anchor Mimics
Our goal was to produce lipidated peptides as GPI anchor
mimics that would on the one hand target semisynthetic
PrP proteins to membranes and, preferably, to liquidChemistry & Biology 14, 994–1006ordered (cholesterol- and glycosphingolipid-rich) do-
mains. On the other hand, a site-specifically introduced
fluorescent label should allow for in vitro and in vivo track-
ing of semisynthetic PrP equipped with GPI anchor ana-
logs. These goals were achieved by testing a variety of
different peptide sequences with one or two palmitoyl
modifications that lead to a high affinity for liposomes as
well as cell membranes [33]. Peptide synthesis was car-
ried out by using the Fmoc-protection strategy, and incor-
poration of modifications such as fluorescent dyes and
alkyl chains was achieved by applying orthogonal and
pseudo orthogonal side chain-protection schemes. How-
ever, introducing two hexadecane chains into these mem-
brane anchor peptides decreased their solubility in deter-
gent and organic, solvent-free aqueous buffer systems
dramatically and thereby prevented efficient ligation reac-
tions with rPrP thioesters. In order to overcome these sol-
ubility problems, a short, oligoethylene glycol-like solubili-
zation tag was introduced at the C terminus of the peptide,
leading to a large increase in solubility (Figure 2A) [34, 35].
Using this strategy, ligation reactions could be carried out
in the absence of detergent and organic solvent, and
yields could be increased 4-fold. In Figure 2B, all peptides
used as GPI anchor mimics are depicted; all of these pep-
tides carry an N-terminal cysteine residue required for, September 2007 ª2007 Elsevier Ltd All rights reserved 995
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Semisynthesis of Lipidated Prion ProteinFigure 2. GPI Anchor-Mimicking Peptides
(A) Synthesis scheme of GPI anchor mimics. After coupling of three polyethyleneglycol polyamide building blocks as solubilization tags, a short
peptide is assembled by Fmoc-based solid-phase peptide synthesis. Precleavage modification includes the coupling of two palmitoyl groups as
membrane anchors and, in certain cases, the coupling of a fluorophore.
(B) Peptides used as GPI anchor mimics. In cases in which fluorescent labels are indicated, variants with and without such labels have been prepared.
(C) Native chemical ligation between DnaEC-thioester and GPI anchor mimic peptide 3 to produce one of the DnaEC-GPI anchor fusion peptides for
trans-splicing reactions.
(D) RP-HPLC chromatogram of the DnaEC-GPI anchor fusion construct after purification (left) and the corresponding ESI-mass spectrum of this
compound (theoretical mass: 7051.8 Da; right).native chemical ligation. Whereas peptide 1 contains only
one palmitoyl group, peptides 2–5 share similar design
features, including a tobacco etch virus (TEV) protease
recognition site (ENLYFQ), two ivDde-protected lysine
residues for attaching two palmitoyl chains, and one lysine
residue protected with Mmt as a potential fluorescence-
labeling site. Additionally, C-terminal polyethyleneglycol
polyamide oligomer (PPO) modification is introduced to
facilitate the handling and solubilization of peptides 2–5.
The functional groups are separated by spacer amino
acids. Peptide 2 enables the cleavage of fluorescent label
and palmitoyl groups from rPrP by proteolysis, whereas,
with peptide 3, the same cleavage reaction keeps the fluo-
rescent label on rPrP. Peptide 4 allows for the removal of
the solubilization tag (PPO3), and peptide 5 resembles
peptide 2, except that the fluorescent label is omitted.
Synthesis and RP-HPLC purification of these GPI
anchor mimics produced pure compounds that were996 Chemistry & Biology 14, 994–1006, September 2007 ª200obtained with yields ranging from 15% to 40% based on
the amount of crude peptides. GPI anchor mimics 2–5
strongly associate with lipid bilayers, as was demon-
strated by cell membrane binding studies. The corre-
sponding nonpalmitoylated peptides did not associate
with cell membranes at all (Figure S1, see the Supplemen-
tal Data available with this article online).
In order to use the GPI anchor-mimicking peptides for
our trans-splicing strategy, the C-terminal domain of the
DnaE split intein (DnaEC) had to be connected with the N
terminus of these peptides. This linkage was established
by ligating the DnaEC-peptide thioester (synthesized by
Boc-solid-phase peptide synthesis [SPPS]) to the GPI
anchor mimic peptides 2–5. Figure 2C illustrates this reac-
tion with GPI anchor mimic 5. The ligation reaction was
tested under a variety of conditions. A buffer system con-
taining 6 M guanidine hydrochloride (GdnHCl) and 300
mM NaPi at pH 7.5 with thiophenol as ligation mediator7 Elsevier Ltd All rights reserved
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Semisynthesis of Lipidated Prion ProteinFigure 3. Expressed Protein Ligation to Generate rPrPPalm
(A) SDS-PAGE of the rPrP-GyrA intein fusion protein after expression (lane 2, 8 ml; lane 3, 4 ml) and after inducing the cleavage reaction in 4 M urea
buffer (pH 8.0) by adding 250 mM Mesna for 20 hr (lane 1). The band with an apparent molecular weight of 16 kDa corresponds to rPrP thioester,
whereas the band at 30 kDa represents the GyrA intein.
(B) ESI-MS analysis of purified rPrP Mesna thioester (theoretical mass: 16,459.2 Da).
(C) ESI-MS of rPrPPalm carrying the GPI anchor mimic 1 with only one palmitoyl group and a C-terminal His6 tag (theoretical mass: 17,741.9 Da).
(D) CD spectrum of refolded rPrPPalm (with GPI anchor mimic 1) in 20 mM NaOAc (pH 5.0).gave the best results, with yields of60%. The addition of
detergent did not increase reaction yields when peptides
containing a solubilization tag were used. By contrast, ini-
tial ligation experiments performed with peptides not
equipped with a solubilization tag required the addition
of detergents such as dodecylmaltoside (DDM) in order
to obtain any ligation product. Adding lipids such as dode-
cylphosphocholine (DPC) to the ligation mixture had a ben-
eficial effect on the ligation yield (an increase of up to 80%
was observed in the case of peptide 4). However, removal
of DPC turned out to be highly problematic; therefore, liga-
tions were carried out in the absence of any detergents or
lipids. The purified fusion peptides consisting of the
DnaEC domain and the GPI anchor mimics 2–5 were ob-
tained in reasonable purity and with yields between 18%
and 30% (Figure 2D). The identity of the ligation products
was confirmed by electrospray mass spectrometry, as
shown for DnaEC-5 in Figure 2D.
Expression of PrP-Intein Fusion Proteins
and Ligation Reactions
Murine PrP90-232 (rPrP) was expressed in E. coli as a
fusion construct with the GyrA mini-intein from Mycobac-Chemistry & Biology 14, 994–10terium xenopi. For this purpose, rPrP(90–232) was cloned
into a modified pTXB3-vector (New England Biolabs) con-
taining, in this order, the GyrA intein, a hexahistidine tag,
and a chitin-binding domain (CBD) (Figure 1A). The fusion
protein was expressed in inclusion bodies that could be
solubilized in buffers containing 8 M urea or 8 M GdnHCl.
Purification was achieved by Ni-NTA-based affinity chro-
matography. Productive cleavage of this fusion construct
was observed after reducing the urea concentration down
to 4 M in the presence of 250 mM mercaptoethanesulfo-
nate (Mesna) (Figure 3A) [36]. No cleavage was observed
in GdnHCl-containing buffers, even at concentrations of
2 M, at which the rPrP-GyrA fusion protein was still
soluble. The resulting rPrP thioester was purified by RP-
HPLC (isolated yield 25%) and was used for native
chemical ligation reactions with GPI anchor mimics 1–5.
A typical electrospray mass spectrum of purified rPrP
thioester is shown Figure 3B.
Lipidated rPrPPalm constructs were obtained with yields
of 30% when ligation reactions were carried out in 8 M
urea buffers containing 17 mg/ml DPC as detergent (see
Experimental Procedures). Figure 3C depicts an electro-
spray mass spectrum of the ligation product of rPrP06, September 2007 ª2007 Elsevier Ltd All rights reserved 997
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Semisynthesis of Lipidated Prion ProteinFigure 4. Protein Trans-Splicing to Generate rPrPPalm
(A) SDS-PAGE of Ni-NTA purification of rPrP-DnaEN fusion protein. Lane 1, flowthrough; lane 2, wash step; lane 3, elution from Ni-NTA.
(B) SDS-PAGE of rPrP-DnaEN trans-splicing with DnaEC-GPI anchor mimic 5 in 4 M urea-containing buffer (left gel, lane 3, 4 ml; lane 4, 8 ml) or
chaotrope-free buffer (right gel, lane 1) and the purified rPrP-DnaEN fusion construct (left gel, lane 1, 8 ml; lane 2, 4 ml; right gel, lane 2).
(C) SDS-PAGE of purified rPrPPalm (with nonfluorescent GPI anchor mimic 5) in lane 1.
(D) CD spectrum of rPrPPalm in DOPC liposomes in 150 mM NaCl, 50 mM Tris-HCl (pH 8).thioester and GPI anchor peptide 1. Two mass peaks can
be identified in the deconvoluted spectrum, one that cor-
responds to the theoretical mass of 17,743 Da, and a sec-
ond one with a mass of 17,786 Da. This mass increase of
43 Da is most likely caused by carbamylation of rPrPPalm,
at a primary amino group, a typical side reaction when
handling proteins for extended periods of time in urea-
containing buffers. The site of modification was not further
investigated. After refolding in 20 mM NaOAc buffer at
pH 5, CD spectroscopic measurements revealed a pre-
dominantly a-helical structure of this rPrPPalm variant,
corresponding to the cellular form of PrP (Figure 3D).
Reconstitution into 1,2-dioleoyl-sn-glycero-3-phospho-
choline (DOPC) liposomes and subsequent ultracentrifu-
gation proved that almost 50% of the single-palmitoylated
rPrPPalm remained in the supernatant and did not effi-
ciently attach to the liposomes (data not shown), in accor-
dance to previous investigations on lipidated Ras [37].
In order to produce lipidated rPrPPalm via a trans-splicing
approach, a fusion construct of rPrP with the N-terminal
part of the naturally occurring split intein DnaE from Syne-
chocystis (DnaEN) was cloned into the vector pTXB3. The
rPrP-DnaEN fusion construct was also expressed as insol-
uble aggregates in E. coli and required a solubilization
step in 8 M GdnHCl, followed by Ni-NTA affinity purifi-998 Chemistry & Biology 14, 994–1006, September 2007 ª200cation (Figure 4A). Partial refolding of the fusion protein
and generation of a functional split intein was achieved
in two different ways. In a first attempt, the chaotrope con-
centration was reduced stepwise to 4 M urea by dialysis.
At 4 M urea, trans-splicing was observed when adding
DnaEC peptide to the rPrP-DnaEN fusion construct (Fig-
ure 4A). Trans-splicing was almost quantitative (90%)
under these conditions, but it was very slow. A second
strategy proved more successful and led to almost quan-
titative folding of rPrP-DnaEN by diluting the purified pro-
tein 10-fold into a glutathione- and L-arginine-containing
buffer. Subsequent dialysis against a Tris-buffered solu-
tion (pH 7.5) gave active rPrP-DnaEN fusion proteins that
produced the trans-splicing product with similar yields
(90%, Figure 4B). Nevertheless, the chaotrope-free
splicing reaction was 4 times faster when compared to
the reaction in 4 M urea (1 day compared to 4 days), and
no carbamylation was observed when using the second
strategy. Different detergents were also tested, and non-
ionic ones such as octylglycoside (OG) and DDM gave
the best results, with yields around 50%–90% based
on the splicing product rPrPPalm. However, to achieve
these high trans-splicing yields, it was necessary to add
low concentrations (5–10 mM) of reducing agents such
as MESNA, DTT, or TCEP. Similar trans-splicing reactions7 Elsevier Ltd All rights reserved
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construct attached to DOPC vesicles and the subsequent
addition of rPrP-DnaEN, leading to similar yields to those
described for detergent-containing buffers. Due to these
advantages, all further experiments were carried out with
lipidated rPrP produced by trans-splicing under chaotrope-
free conditions with GPI anchor mimic 5. rPrP variants with
GPI anchor mimics 2–4 behaved similarly to rPrPPalm
equipped with 5 in folding and aggregation assays.
Purification and Folding of rPrPPalm
Purification of rPrPPalm was achieved by Ni-NTA affinity
chromatography to remove unreacted rPrP-DnaEN and
DnaEN and subsequent gel filtration. The purified material
was analyzed by SDS-PAGE (Figure 4C). In order to obtain
correctly folded rPrPPalm, the purified protein was first un-
folded in a buffer containing 6 M GdnHCl as well as gluta-
thione and its oxidized form (GSSG). Subsequently, the
solution was rapidly diluted into sodium acetate buffer
(20 mM, pH 5) containing DOPC vesicles. This refolding
procedure was initially tested with rPrP in the absence of
lipid vesicles, and the resulting rPrP was checked by CD
spectroscopy as well as NMR experiments, which verified
folding into the predominantly a-helical cellular form (data
not shown). For rPrPPalm, CD spectroscopy was carried
out in a similar buffer containing DOPC vesicles confirm-
ing the a-helical structure of rPrPPalm after refolding
(Figure 4D). These rPrP and rPrPPalm preparations were
stable at pH 5.0 for up to 48 hr at 4C and could also be
stored at 80C for prolonged periods of time without
any indication of aggregation. This folding procedure is
based on results obtained for nonlipidated PrP samples
[38]. No difference between the secondary structure of
membrane-bound rPrPPalm and rPrP was found in our
experiments, which is consistent with data reported previ-
ously for membrane-associated variants of PrP [21–23].
Aggregation into a proteinase K (PK)-resistant rPrP
variant (rPrPres) can be induced by adding chaotrope mix-
tures such as 3 M urea/1 M GdnHCl at slightly acidic pH.
Formation of rPrPres is observed in GdnHCl/urea-contain-
ing buffers after 15 hr for rPrP in the presence and
absence of liposomes and also after 15 hr for rPrPPalm in
the absence of liposomes. Significantly, under similar
conditions (same concentration at 37C), the formation
of PK-resistant rPrPPalm is much slower in the presence
of liposomes. Resistant material is not observed after 15
hr, but only after 36 hr (Figure 5A). These results indicate
that membrane anchoring of rPrPPalm reduces the speed
of aggregate formation, thereby slowing down the conver-
sion into rPrPres. Accordingly, results were obtained by
using thioflavin T fluorescence assays that indicate a faster
aggregation of rPrP in buffers with and without liposomes
(aggregation starts after 1 hr at 37C) when compared to
rPrPPalm in buffer with liposomes (aggregation starts after
15 hr at 37C) (Figure 5B). Such a faster aggregation was
also observed for rPrPPalm in the absence of DOPC lipo-
somes (Figure 5B). Therefore, a direct influence of lipo-
somes on aggregation rates of rPrP without a membrane
anchor can be excluded.Chemistry & Biology 14, 994–100Vesicle Association
Reconstitution of rPrPPalm (rPrP + GPI anchor mimic 5was
used here) into liposomes was achieved by dilution of a
detergent-containing solution of rPrPPalm into a liposome-
containing buffer and subsequent removal of DDM by
treatment with biobeads. Membrane insertion of rPrPPalm
with two palmitoyl modifications is almost quantitative.
Unambiguous proof that rPrPPalm is attached to DOPC
vesicles via its two C-terminal palmitoyl chains was
provided by sucrose density gradient centrifugation.
rPrPPalm-containing fractions were obtained at densities
of 10%. Treating these vesicles for 6 hr with TEV prote-
ase removed rPrP from its lipid anchor, and it is therefore
found in the top layer of the sucrose gradient (Figure 5C).
These data clearly indicate that proteolytic removal of the
palmitoyl anchor from rPrPPalm leads to detachment of
rPrP from the vesicles and proves that the rPrPPalm-vesicle
interaction is mediated by the alkyl chains of the palmitoyl
groups. Therefore, unspecific hydrophobic interactions of
rPrP with vesicle membranes can be ruled out.
Cellular Uptake
Strong interactions of the double-palmitoylated and
fluorescently labeled peptides and proteins with cell and
artificial membranes were already demonstrated (Supple-
mental Data) [33]. However, no evidence has so far been
presented that rPrPPalm modified with a GPI anchor mimic
can be efficiently attached to cells via insertion into their
membrane. In order to demonstrate that the GPI anchor
mimic 5 confers the ability to insert into cell membranes
to rPrPPalm, we incubated murine neuronal cells (N2a) (Fig-
ure 6) and human embryonic kidney (HEK293T, data not
shown) cells with 0.01 mg/ml rPrPPalm suspended in a lipo-
some preparation in phosphate-buffered saline (PBS). In
control experiments, rPrP, devoid of the GPI anchor
mimic, was used at similar concentrations (Figure 6). It
should be noted that transfer efficiencies were highly
dependent on the composition of the liposomes used for
protein transfection assays. Initial experiments with
rPrPPalm reconstituted in DOPC liposomes as well as
with rPrPPalm in detergent micelles such as OG and
DDM did not lead to any transfer of soluble rPrPPalm into
live cells. In the case of DOPC liposomes, no rPrPPalm
was detected in the cells—neither by western blot analysis
of lysed cells, nor by immunofluorescence analysis of
fixed cells. For rPrPPalm, in detergent-containing buffers,
western blot analysis indicated that a small amount of
rPrPPalm was associated with the cell debris after lysis;
however, membrane extraction with Triton X-100 and
sodium deoxycholate (DOC) did not produce any soluble
rPrPPalm. This result and the fact that viability of the cells
could only be maintained for a period of 1 to a maximum
of 4 hr in the presence of detergent made clear that a
different strategy was required to efficiently transfer
rPrPPalm.
Cellular uptake was achieved by adding rPrPPalm and
rPrP(90–232) samples to the growth media at pH 7.3 after
reconstitution into a liposome-forming transfection agent
(Pro-Ject, Pierce) and incubation at 37C in Petri dishes.6, September 2007 ª2007 Elsevier Ltd All rights reserved 999
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Semisynthesis of Lipidated Prion ProteinFigure 5. In Vitro Analysis of rPrPPalm
(A) Proteinase K resistance of rPrP (left) and rPrPPalm (right) after incubation in aggregation buffer (3 M urea, 1 M GdnHCl, 150 mM NaCl, 20 mM NaPi
[pH 6.8]). Proteinase K-resistant rPrP is already observed after 15 hr of incubation at 37C in the presence and absence of liposomes; however, PK-
resistant rPrPPalm only appears after 36 hr of incubation in the presence of liposomes.
(B) Thioflavin T (ThT) assay carried out at 37C with aggregation buffer. An increase in ThT fluorescence at 488 nm indicates the presence of aggre-
gated material. A steep increase in absorbance is observed for rPrP (left panel) after 30 min in the presence (red circles) and absence (black squares)
of liposomes, whereas rPrPPalm aggregation leads to an increase in ThT fluorescence after 15 hr in the presence of liposomes (right panel, red circles).
In the absence of liposomes, rPrPPalm aggregation starts after 1–2 hr (black squares).
(C) Sucrose gradient centrifugation of rPrPPalm, rPrPPalm treated with tobacco etch virus (TEV) protease for 6 hr at room temperature, and rPrP in
DOPC liposomes. A capital ‘‘M’’ indicates the position of the prestained marker on the depicted western blots. rPrPPalm associates with DOPC lipo-
somes and can be found at concentrations of 10% sucrose. rPrPPalm after treatment with TEV protease, which cleaves rPrP from its GPI anchor mimic
C-terminal peptide, is found at the lowest sucrose concentration, similar to rPrP, which should not associate with liposomes.After 2 and 5 hr, respectively, cells were washed, har-
vested, and lysed in a buffer containing 0.5% Triton X-
100 and 0.5% DOC in PBS. This buffer is known to effi-
ciently solubilize native PrPC and should therefore also
be able to extract rPrPPalm if it is bound to the membrane
in a nonaggregated state [39]. The cell lysate was fraction-
ated by centrifugation, and PrP present in the detergent-
soluble (Sup) and -insoluble fraction (Pellet) was detected
by western blot with the monoclonal antibody 3F4. This1000 Chemistry & Biology 14, 994–1006, September 2007 ª200antibody is specific for the externally added rPrPs and
does not react with endogenous mouse PrPC [40].
After addition to the cells, rPrP could only be recovered
in a detergent-insoluble conformation (Figure 6A, pellet),
indicating a rapid misfolding after dissolving rPrP in cell
culture media. In contrast to this observation, up to 50%
of the total rPrPPalm was found in the supernatant after
5 hr of incubation. Obviously, rPrPPalm maintains a correct
conformation, most likely by integrating into the plasma7 Elsevier Ltd All rights reserved
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Semisynthesis of Lipidated Prion ProteinFigure 6. Cellular Uptake of rPrPPalm into N2a Cells
N2a cells were transfected with rPrPPalm and rPrP and incubated for 2 hr and 5 hr, respectively, at 37C.
(A) Cells were harvested, lysed in cold buffer C, and fractionated by centrifugation. rPrP present in the detergent-soluble (sup) and -insoluble (pellet)
fraction was analyzed by western blot with the mAb 3F4. As input controls, recombinant PrPs were incubated in the absence of cells, precipitated with
TCA, and analyzed by western blot.
(B) For immunofluorescence studies, cells were grown on coverslips, incubated with rPrPs, fixed, and permeabilized. rPrP and rPrPPalm were
detected with the mAb 3F4. Nuclei were stained with DAPI.
(C) Higher-resolution images of N2a cells transfected with PrPC and rPrPPalm. mAb 3F4 was used to detect PrPC and rPrPPalm.
(D) Western blot analysis of rPrP and rPrPPalm after extraction from cell membranes with cold Triton X-100 and a subsequent flotation assay in a
sucrose gradient.Chemistry & Biology 14, 994–1006, September 2007 ª2007 Elsevier Ltd All rights reserved 1001
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fected N2a cells with cold Triton X-100-containing buffer,
followed by a flotation assay on a sucrose gradient, was
used to determine if rPrPPalm associates with detergent-
insoluble membrane domains similarly to what is
described for rPrPC [41, 42]. In this assay, rPrP remains
in the pellet of the low-spin centrifugation and does not
float in the sucrose gradient, whereas rPrPPalm floates in
fractions 1–4 at concentrations of 30%–40% sucrose
(Figure 6D). This result indicates a difference between
PrPC and rPrPPalm that is probably due to the chemical
nature of the native GPI anchor and the GPI anchor mimic.
In order to analyze the cellular localization of externally
added rPrP and rPrPalm, indirect immunofluorescence ex-
periments were performed. In N2a cells incubated with
rPrPPalm as described above and treated with the antibody
3F4, which is specific for rPrPPalm, cell boundaries are
clearly visible, revealing that the majority of rPrPPalm is
located at the plasma membrane (Figure 6B). However,
for rPrP, no staining of cell membranes was observed. In
this case, only small, bright spots, which are probably
due to large rPrP aggregates, occurred. Similar pictures
were obtained by Breydo et al. with myristoylated rPrP
[28]; but, in this work, no membrane extraction experi-
ments, which could have distinguished between soluble
and insoluble PrP associated with cell membranes, were
described. DAPI staining confirmed that all cells were
viable, and a negative control demonstrates that no en-
dogenous PrP was picked up by this method (Figure 6).
Higher-resolution images of N2a cells transfected with
rPrPPalm and cellular PrpC (in mammalian expression vec-
tor pcDNA3.1 [18]) clearly demonstrate that transient
transfection with DNA coding for PrPC carrying the 3F4
epitope and detection with the same antibody (3F4) leads
to a similar cell surface-staining pattern as transfection
with rPrPPalm (Figure 6C).
DISCUSSION
Previously reported approaches to obtain recombinantly
expressed, membrane-bound PrP relied on the formation
of disulfide bonds between either a PrP variant with a 6
amino acid C-terminal extension consisting of 5 glycine
residues and a C-terminal cysteine with a thiol-reactive
lipid (N-((2-pyridyldithio)-propinyl)-1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine) already incorporated
into liposomes, or a PrP variant containing a mutation of
the C-terminal serine residue 231 to a cysteine that was
reacted with 3-(hexadecane-1-sulfonyl)-2-(hexadecane-
1-sulfonylmethyl) propionic acid linked to a methanethio-
sulfonate reactive group via a polyethylene glycol linker
[22, 23]. Both approaches suffer from both the fact that
a free thiol group has to be maintained at the C terminus
of rPrP while an intact disulfide bridge must be conserved
to ensure structural integrity of the protein during folding
and subsequent measurements as well as from the sensi-
tivity of the formed disulfide bond between rPrP and the
respective membrane anchor to reducing conditions. A
recently described myristoyl-modified PrP variant was1002 Chemistry & Biology 14, 994–1006, September 2007 ª200produced by reacting N-(2-myristoylamidoethyl-)malei-
mide with PrP carrying a cysteine at position 230 [28].
The two semisynthetic strategies that are described
here do not require the maintenance of such a delicate
equilibrium between a free thiol group and an intact disul-
fide bond inside the recombinantly expressed PrP mole-
cule; however, for one of them, a C-terminal thioester
moiety is needed to perform a native chemical ligation
reaction with a peptide containing an N-terminal cysteine
residue, and this reaction requires the addition of nucleo-
philic thiols (and therefore reducing conditions) in order to
accelerate the ligation reaction and suppress unwanted
side reactions (Figure 1A) [30]. The second strategy, in-
volving the split intein approach, does not require isolation
of such a thioester species and strongly reducing condi-
tions can be avoided, which allows the internal disulfide
bond of folded rPrP to stay intact (Figure 1B). Furthermore,
the absence of high concentrations of thiols would allow
for the extension of this method toward in vivo applica-
tions [32]. In both cases, a stable amide bond results
from these synthesis strategies and provides a distinct
advantage over reduction-prone disulfide bonds, espe-
cially in in vivo applications.
In this study, both approaches led to recombinant
a-helical PrP with a variety of C-terminal GPI anchor
mimics (rPrPPalm) in multimilligram amounts, with total
yields of 10% based on the expression of rPrP fusion
proteins in E. coli. To our knowledge, the resulting rPrPPalm
variants constitute a first example of applying EPL and
trans-splicing toward proteins that are, due to their dispo-
sition to aggregate, inherently difficult to handle and that
play an important role in conformational protein diseases.
A series of denaturation and renaturation steps was
required to obtain functional rPrP-intein fusion proteins
as well as folded rPrPPalm.
The system finally chosen to produce rPrPPalm with GPI
anchor mimic 5 for aggregation and transfection assays
consisted of rPrP-DnaEN fusion protein and the DnaEC-
GPI anchor mimic fusion peptide. Trans-splicing reactions
were carried out in chaotrope-free, detergent-containing
buffer with low concentrations of reducing reagents. The
positive effect of these reducing reagents on trans-splic-
ing yields can most likely be explained by keeping cyste-
ine side chains that are involved in trans-esterification
steps during trans-splicing in their active, reduced state
(Figure 1B). The observation that trans-splicing occurs
efficiently in buffers containing DOPC liposomes with one
vesicle-anchored component points toward the feasibility
of such trans-splicing reactions in membranes of live cells
if the fully functional, reactive cysteine side chains can be
retained.
We have tested the tendency of vesicle-attached
rPrPPalm to aggregate by two different, well-established
methods, one being proteinase K resistance and the other
thioflavin T binding [43]. Both assays provide evidence
that aggregation of vesicle-attached rPrPPalm proceeds
slower (by a factor of 5–6) than aggregation of rPrP in
control experiments at similar concentrations. We deduce
from these experiments that membrane-attached rPrPPalm7 Elsevier Ltd All rights reserved
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due to stabilizing effects of the lipid bilayer. The effect of
membrane association of PrP variants on their tendency
to form proteinase K-resistant aggregates is still a matter
of debate since it has been reported that no influence of
membrane anchoring on PrP stability can be observed
for lipidated rPrP [22]. However, data based on either
rPrP equipped with a lipid anchor or PrP from mammalian
cells carrying a GPI anchor suggest that membrane an-
choring protects PrP from conversion into its proteinase
K-resistant state [21, 23, 44]. These latter results are in
agreement with the effect observed for rPrPPalm in which
aggregation occurs much slower when exposed to condi-
tions that trigger aggregation of rPrP. The influence of lipid
composition and the charge of the lipid head groups as
well as localization of rPrPPalm in ordered membrane
domains on PrP conversion are still controversially dis-
cussed. This discussion might possibly be resolved by
further cell-based studies with rPrPPalm. It is important to
note that no binding of rPrP to DOPC liposomes was
observed, and that rPrPPalm was detached from such lipo-
somes by treatment with TEV protease by taking advan-
tage of the designed cleavage site in our GPI anchor mimic
5. This indicates that the N-terminally truncated rPrP(90–
232) variant used here does not insert into zwitterionic li-
posomes, in contrast to reports about rPrP in negatively
and uncharged membranes [19, 44]. Furthermore, it can
be concluded that rPrPPalm is solely attached to the out-
side of the vesicles, and that only a minor amount of
rPrPPalm, which is not detected by western blot, is found
in the buffer, indicating its very strong binding to the lipid
bilayer.
Having established the specific attachment of rPrPPalm
to lipid bilayers, the incorporation into the plasma mem-
brane of live cells was elucidated. This step is crucial for
further investigating prion biochemistry. Anchoring of
rPrPPalm into the cell membrane is inherently difficult since
transfer of rPrPPalm from one membrane environment to
the outer leaflet of the cell membrane has to occur, as it
was demonstrated by the unsuccessful attempts with dif-
ferent lipids and detergents. Finally, a protein transfection
agent (Pro-Ject, Pierce) that consists of cationic lipids
turned out to be successful. An explanation for this behav-
ior could be that a direct transfer from liposomes to the
plasma membrane only rarely (if at all) occurs. However,
if fusion is facilitated, in the present case due to electro-
static attraction between positively charged Pro-Ject
liposomes and negatively charged cell membranes, an
efficient delivery of rPrPPalm can occur. It is important to
note that proof of correct incorporation of rPrPPalm into
the plasma membrane cannot be provided by simple indi-
rect immune fluorescence with an rPrP-specific antibody.
This method does not allow for the distinction between
aggregated rPrPPalm associated with cell surfaces and
soluble rPrPPalm attached to the membrane via its GPI
anchor mimic. Therefore, we included control experi-
ments based on extraction of cell membranes with Triton
X-100 and DOC-containing buffers. These experiments
provided proof that a soluble variant of rPrPPalm isChemistry & Biology 14, 994–1006attached to the membrane, and western blot analysis of
membrane extracts and pellets is crucial to gain informa-
tion about the state of membrane-associated rPrP vari-
ants. A flotation assay revealed more evidence that
rPrPPalm associates with the cell membrane. Although
rPrPPalm was detected at different sucrose concentrations
than PrPC, this was to be expected because of the differ-
ent chemical nature of the GPI anchor mimic.
The similar cell surface-staining patterns of N2a cells
transfected with rPrPPalm and PrPC provide additional
proof for similar membrane insertion of semisynthetic
rPrPPalm with a GPI anchor mimic and PrPC with a native
GPI anchor. The successful transfer of rPrPPalm into cell
membranes of two different cell lines paves the way for
future studies of the conversion process of membrane-
anchored rPrPPalm in live cells either by western blot
analysis of fractionated cell lysates or, with much higher
resolution, by in vivo fluorescence analysis of fluores-
cently labeled rPrPPalm variants.
SIGNIFICANCE
Toxic conformations of cellular proteins are the cause
for several severe neurodegenerative diseases for
which no therapeutic regiment exists to date. The
prion protein (PrP) is special among these proteins
because it is an infectious agent that can convert cor-
rectly folded PrP into its toxic isoform. The elucidation
of this process is of central importance for under-
standing the nature of toxic protein conformations
and the mechanism of their generation. The cellular
form of PrP itself is probably converted into its mis-
folded isoform in its natural environment, the outer
leaflet of the cell membrane. In order to elucidate
this process of conversion and the subsequent pro-
cessing inside cells, we have established two semi-
synthesis strategies to obtain multimilligram amounts
of C-terminally modified recombinant PrP. These
strategies allow for the synthesis of correctly folded
rPrP variants with GPI anchormimics at their C termini
(rPrPPalm) that attach to liposomes via their GPI anchor
mimics and thereby afford the possibility to study
membrane-attached rPrP. Such liposome attachment
slows the formation of proteinase K-resistant aggre-
gates of rPrPPalm in comparison to soluble rPrP,
indicating a partial protection of the predominantly
a-helical, cellular form of rPrPPalm. An important step
toward the elucidation of prion conversion and prion
turnover was achieved by a successful transfer of
semisynthetic rPrPPalm into the plasma membrane of
live cells.
EXPERIMENTAL PROCEDURES
All chemicals used were obtained from Sigma-Aldrich and Novabio-
chem in the highest purity available if not otherwise stated.
Peptide Synthesis
Solid-phase peptide synthesis was performed on a custom-modified
433A peptide synthesizer from Applied Biosystems, by using Boc, September 2007 ª2007 Elsevier Ltd All rights reserved 1003
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by manually using Fmoc chemistry [46]. Cleavage of ivDde-protecting
groups was carried out with 3% hydrazine in dimethylformamide
(DMF), and palmitoylation was done with 20 eq. palmitoylchloride, 20
eq. HOBT, and 22 eq. triethylamine in dichloromethane (DCM)/DMF
(3:1) for 4 hr. Removal of Mmt was achieved by treatment with acetic
acid, trifluorethanol, and DCM (1:2:7), after neutralizing the resin with
10% DIEA in DMF. Cy5 coupling was performed by the addition of
Cy5-NHS for 24 hr. Peptides synthesized by Boc chemistry were
deprotected and simultaneously cleaved from the resin by using anhy-
drous hydrogen fluoride, whereas those synthesized by Fmoc chemis-
try were cleaved by 2.5% H2O and 5% TIS in TFA. Crude products
were subsequently precipitated with diethyl ether, dissolved in 50%
aqueous acetonitrile (0.1% TFA), and lyophilized. Peptides were puri-
fied by RP-HPLC on C4 columns from Vydac by using linear gradients
of buffer B (acetonitrile with 0.08% trifluoroacetic acid) in buffer A
(water with 0.1% trifluoroacetic acid).
HPLC and Mass Spectrometry
HPLC analysis of peptides was performed on an analytical RP-C4
column (Vydac) (Hesperia, CA) at a flow rate of 1 ml/min over 30 min
with a gradient from 5% to 80% (v/v) buffer B in buffer A. Peptide
and protein masses were determined by electrospray ionization
mass spectrometry on an LCQ Advantage Max (Finnigan) operating
in positive ion mode. The molecular masses were deconvoluted from
the charged ion spectra.
Native Chemical Ligation
Native chemical ligations of synthetic peptides were carried out in 6 M
GdnHCl, 300 mM NaPi, 1% (v/v) thiophenol (optional addition of 17
mg/ml dodecylphosphocholine [DPC]) at pH 7.4–7.7 by using concen-
trations of 5–6 mM of C- and N-terminal peptides [30]. Native chemical
ligation reactions of rPrP thioester with peptides 1–5 were carried out
in 8 M urea, 300 mM NaPi, 17 mg/ml DPC, and 1% (v/v) thiophenol at
pH 7.8 and concentrations of 1 mM rPrP thioester and 1.5–2 equiva-
lents of peptides 1–5.
Reactions were quenched by the addition of 3 volume equivalents of
ligation buffer and 20% (v/v) b-mercaptoethanol. The ligation mixtures
were purified by RP-HPLC on a C4 column from Vydac with linear
gradients.
Expression and Purification of Recombinant rPrP
Recombinant murine rPrP(90–232) was cloned into a modified pTXB3
vector (New England Biolabs) containing the GyrA mini-intein and a
chitin-binding domain (CBD) with an additional His tag between
them. Expression was carried out in E. coli BL21(DE3), and cells
were harvested and lysed as described below. Solubilization of inclu-
sion bodies was achieved in 8 M urea, followed by affinity purification
with Ni-NTA (QIAGEN). After dialysis against a buffer containing 4 M
urea and 50 mM Tris-HCl (pH 8.0), a 50 mM NaCl addition of 250
mM MESNA was used to form the rPrP thioester. The rPrP thioester
was purified via a C4-RP-HPLC column (Vydac) by applying a gradient
of 35% buffer B in buffer A to 70% buffer B in buffer A over 60 min.
Typical yields were 20 mg of rPrP-GyrA fusion construct from 1 l of
E. coli culture that resulted in 2 mg of HPLC-purified rPrP thioester.
Recombinant murine rPrP(90–232) was cloned into the pTXB3 (New
England Biolabs) vector and expressed in E. coli BL21(DE3)RIL as a
fusion protein with the DnaEN split intein from Synechocystis and an
additional His tag. Protein expression was induced with IPTG and
gave20 mg rPrP-DnaEN fusion protein per 1 l E. coli culture. The cells
were harvested by centrifugation and lysed in a M110S Microfluidizer
(Microfluids Corporation, Newton). rPrP-DnaEN-His was deposited in
inclusion bodies and had to be dissolved in 8 M GdnHCl prior to
Ni-NTA (QIAGEN) purification.
Folding of rPrP-DnaEN-His
The denatured protein was diluted 1:10 to a final concentration of 0.1
mg/ml into a buffer containing 0.6 M L-arginine, 50 mM Tris-HCl (pH1004 Chemistry & Biology 14, 994–1006, September 2007 ª28.6), and 5 mM GSH/0.5 mM GSSG. The solution was incubated for
12 hr at 4C. L-arginine and the redox agents were removed by dialysis
against 50 mM Tris-HCl buffer (pH 7.5). Folding yields were 50%,
leading to 10 mg rPrP-DnaEN for trans-splicing reactions from 1 l E.
coli culture. The protein solution was concentrated to 10 mM rPrP-
DnaEN-His.
Trans-Splicing of rPrP-DnaEN-His
Protein trans-splicing of rPrP-DnaEN and DnaEC-guanidine hydrochlo-
ride (GPI) anchor mimics was carried out at equimolar concentrations
of 5 mM in 50 mM Tris-HCl (pH 8) (trans-splicing buffer) in the presence
of 50 mM MESNA and optional addition of octylglycoside (OG) or 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC) liposomes. Reactions
were stopped by the addition of SDS sample buffer for SDS-PAGE
analysis or by transfer into 6 M GdnHCl buffer (see below). Purification
was achieved by affinity chromatography with Ni-NTA fast-flow
Sepharose (QIAGEN) in 6 M GdnHCl buffer to remove unreacted
rPrP-DnaEN and DnaEN. Subsequent size-exclusion chromatography
(Superdex 75, Pharmacia) allowed for separation of rPrPPalm.
Folding of rPrPPalm Variants
The proteins were incubated in 6 M GdnHCl, 50 mM Tris-HCl (pH 7.5)
containing 5 mM GSH and 0.5 mM GSSG for 1 hr. Gel filtration was
used to exchange the GdnHCl-containing buffer against 20 mM
NaOAc (pH 5.5) (folding buffer) containing 20 mM OG. The protein
solution was concentrated to 10 mM. Combined yields of the trans-
splicing reaction between rPrP-DnaEN and peptides 1–5 linked to
DnaEC as well as the folding of the resulting splicing products rPrPPalm
were typically 20%, leading to 2 mg rPrPPalm from 1 l E. coli culture.
Preparation of Liposomes
DOPC lipids were solved in DCM, and a thin lipid film was formed by
evaporation of the solvent under rotation in a helium stream. The lipid
film was hydrated in either trans-splicing or folding buffer for 1 hr. For-
mation of small unilamellar vesicles (SUVs) was achieved by sonication
and subsequent centrifugation at 100,000 3 g for 30 min at 22C.
Dynamic Light Scattering
The size of SUVs was checked by dynamic light scattering on a
DynaPro system (Wyatt Technology).
Reconstitution of Lipidated Samples
Lipidated refolded proteins were diluted (10-fold) into a 10 mg/ml SUV
solution. The samples were dialysed overnight against biobeads
(Biorad) containing phosphate-buffered saline (PBS) buffer.
CD Spectroscopy
Far-UV CD spectra were recorded on a Jasco J-715 spectropolari-
meter. Protein concentrations were 0.2 mg/ml in 20 mM NaOAc at
pH 5.5. All spectra were recorded in a 0.1 cm cuvette between 200
and 250 nm.
Fibril Formation
a-helical rPrP and rPrPPalm were dialysed against 3 M urea, 1 M
GdnHCl, 150 mM NaCl, and 20 mM NaPi (pH 6.8) as reported previ-
ously [47]. Samples were incubated at room temperature for 1–4
days. Aggregation was followed by either proteinase K resistance or
thioflavin T fluorescence.
Proteolysis of rPrP and rPrPPalm
Proteinase K (Sigma) was used to digest rPrP variants with a substrate
to enzyme ratio of 50:1 at 37C for 1 hr in 100 mM Tris-HCl (pH 7.5).
Digestion was stopped by the addition of 2 mM PMSF. Treated
samples were analyzed by SDS/PAGE.
ThT Assay
Aliquots withdrawn during incubation of rPrP and rPrPPalm in aggrega-
tion buffer were diluted into 5 mM sodium acetate buffer (pH 5.5) to007 Elsevier Ltd All rights reserved
Chemistry & Biology
Semisynthesis of Lipidated Prion Proteina final concentration of 0.3 mM rPrP and rPrPPalm. ThT (Sigma) was
added to a final concentration of 10 mM. The emission spectra (from
460 nm to 520 nm) were recorded with excitation at 445 nm on a LS
55 Spectrometer (PerkinElmer). The fluorescence intensities at emis-
sion maximum (488 nm) were determined and plotted against time.
Cell Lysis and Western Blot
As described earlier [48], cells were washed twice with cold saline
buffer (PBS), scraped off the plate, pelleted by centrifugation, and
lysed in cold buffer C (0.5% Triton X-100, 0.5% sodium deoxycholate
[DOC] in PBS). After centrifugation, the detergent-soluble and -insolu-
ble fractions were analyzed by western blot. SDS-PAGE and western
blot were described previously [39].
Transfection
Mouse N2a and HEK293T cells were cultivated as described [18]. Cells
were transfected by liposome-mediated transfer by using Pro-Ject
protein transfection reagent according to the manufacturer’s instruc-
tion (Pierce).
Assay for Uptake of rPrPPalm
To examine the amount of untransfected recombinant PrP, the me-
dium was collected and PrP was precipitated with trichloroacetic
acid (TCA) and analyzed by western blot with the monoclonal antibody
3F4. The cells were washed three times with cold PBS, scraped off the
plate, pelleted by centrifugation, and lysed in cold buffer (0.5% Triton
X-100 and 0.5% sodium DOC in PBS). The lysate was centrifuged at
15,000 3 g for 20 min at 4C. After boiling the supernatant and the
pellet in La¨mmli sample buffer, the samples were analyzed by immuno-
blotting.
Indirect Immunofluorescence
As described earlier [49], cells were grown on glass coverslips, fixed
with 3% paraformaldehyde for 20 min, and permeabilized with 0.2%
Triton X-100 for 10 min at room temperature. The primary antibody
was incubated for 45 min at 37C in PBS containing 1% BSA. After
extensive washing with cold PBS, an incubation with Cy3-conjugated
anti-mouse antibody (Dianova) (dilution 1:200) followed at 37C for
30 min. The washed glass coverslips were mounted onto glass slides
and examined by fluorescence microcopy (Axiovert 200 M, Zeiss) by
using the AxioVision 3.0 software.
The plasmid encoding PrPC used as control in immunofluorescence
experiments was described previously [18]. Cultivated N2a and
HEK293T cells were transfected with a total of 1 mg DNA by using a
liposome-mediated method with LipofectAmine Plus reagent (Invitro-
gen) according to the manufacturer’s instructions.
Flotation Assay
Lysis of N2a cells was carried out in 200 ml MBS buffer (25 mM MES,
150 mM NaCl [pH 6.5]) with 1% Triton X-100 at 4C. After low-spin cen-
trifugation (5 min, 500 3 g), 200 ml MBS containing 80% sucrose was
added to the supernatant. The resulting 400 ml was covered with 3 ml
30% sucrose and 1 ml 5% sucrose in MBS buffer.
The resulting step gradient was centrifuged overnight (40,000 rpm,
MLS 50, 4C) and analyzed in 500 ml fractions by western blot as
described above.
Supplemental Data
Supplemental Data include analytical information on the GPI anchor-
mimicking peptides and are available at http://www.chembiol.com/
cgi/content/full/14/9/994/DC1/.
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